OmniRayn
← All repurposing reports
S2 (505(b)(2))

Type 1 Diabetes

Known, approved drugs ranked as repurposing candidates for Type 1 Diabetes — each scored for reversal of the disease expression signature, cytotoxicity-filtered, and prioritized by clinical maturity. Computational, pending wet-lab.

Preview. Candidate identities are shown below. The full ranking, quantified reversal scores, per-candidate mechanistic rationale, ClinicalTrials.gov whitespace detail, and structure-function intelligence are included with the dossier.

Top candidates preview

  1. 1tivozanibApproved
  2. 2epirubicinApproved
  3. 3selumetinibApproved
  4. 4idarubicinApproved
  5. 5atorvastatinApproved
  6. 6topotecanApproved
  7. 7amiodaroneApproved
  8. 8dactinomycinApproved

Full dossier — 147 cytotox-screened candidates

Quantified reversal ranking · mechanistic rationale · CT.gov whitespace · S2 (505(b)(2)) regulatory framing · structure-function intelligence.

Acquire dossier — $3,950